|
Deca and Dianabol
Deca durabolin (nandrolene decanoate), or simply deca, is a great anabolic steroid that is used to gain strength and add mass. It is also a medically favorable steroid since it can be used to reduce joint problems and helps on osteoporosis. It increases calcium and potassium in the body which aids muscle growth and function. This is so because these ions help in release of insulin and transmitting nerve signals. The former helps in increasing the body mass and the latter effect increases strength. It can also be used during radiotherapy of patients with laryngeal cancer since it increases the sensitivity of laryngeal cells to radiotherapy. It can also be used to treat anemia associated with kidney failure.
Patients with breast cancer, diabetes, liver maladies, cardiovascular disease and any kidney problems need to verify first if deca usage is safe for them. Pregnant and nursing women should avoid using it. Also people on growth hormone medication, finasteride or or warfarin should not use deca durabolin because it tends to interact with it.
Deca and dianabol are used together in a mass cycle to elicit maximum muscle gain. Deca or nandrolone decanoate is administered as an intra muscular injection. The drug should also be kept away from bright light such as sunlight and should not be exposed to below freezing temperatures either. The best temperature for storing it is from 15 to 300C.
Nandrolene decanoate is banned in the US and also by the athletic organizations such as the International Olympic Committees for use in athletes. However, its medical benefits give it an advantage. Deca and dianabol usage together is also quite safe as both of them stack well and have few side effects though in excessive amounts, decadurabolin may produce a number of side effects including acne, hair loss, difficulty in passing urine and even impotence in men.
If things go wrong, depression, gastrointestinal discomfort, bleeding and weight gain may occur. In such a case, a physician should be immediately consulted. In children it may promote bone maturation but may fail to increase linear extension of the bone causing them to have a small stature. It may also lead to irregular growth and sexual development in children. If consumed by pregnant women, it may cause masculinization of the fetus.
For therapeutic uses, usually 4 mg of the steroid are prescribed to be taken orally. Doses may be higher if the purpose of use is loss of fat or building muscles. Hemoglobin and serum lipids should be periodically monitored during use.
Articles:
- Quantity vs. Quality: Long-Term Use of Bone-Building Osteoporosis Drugs
- Studies find possible links between prolonged bisphosphonate
treatments
ROSEMONT, Ill., March 10, 2010-Bisphosphonate treatments, proven
to enhance bone density and reduce fracture incidence in
post-menopausal women, may adversely affect bone...
- Teva Announces the Appointment of Dr. Philip Frost As Chairman of Its Board of Directors
- Jerusalem, Israel, March 9, 2010 -
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today
that its Board of Directors received a letter from Mr. Eli Hurvitz
indicating that he wishes to be released from his duties at Teva in
order to...
- PhRMA Statement About Accessing Online Health Information
- Washington, D.C. (March 9, 2010) —
Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President David E. Wheadon
issued the following statement regarding patients’ access to
reliable health information...
- Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
- Collaboration Exploits Cellzome's World-Leading Proteomics
Technology in Epigenetics
CAMBRIDGE, England and HEIDELBERG, Germany, March 10,
2010/PRNewswire/ -- Cellzome today announced that it has formed a
second strategic alliance with...
- Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
- Provides Promising Biologic Intended to Treat Multiple
Sclerosis and Compounds that Complement Abbott's Existing Diverse
Oncology Program
ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9
/PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Facet...
- Catalina Marketing Hires Johnson & Johnson Executive to Lead Health Care Services Division
- ST. PETERSBURG, FL. March 9, 2010– Catalina Marketing
Corporation, the global leader in precision marketing and
shopper-driven media, today announced the appointment of Renee
Selman as President of its health care division, Catalina...
- GSK CEO Andrew Witty Dedicates albendazole Facility in Nashik to WHO?s Global Programme to Eliminate LF
- LONDON, March 8, 2010--GlaxoSmithKline (GSK) CEO Andrew
Witty today dedicated a new production facility at its Nashik site
in India to the manufacture of albendazole, part of a combination
treatment used within the World Health...
- Cardiff University and Merck Serono Launch International Survey For Couples Trying To Conceive
- • Largest study aimed at understanding the fertility
decision-making process of today’s couples trying to conceive
• Survey available in twelve languages on www.startingfamilies.com
Mumbai, India, March 9, 2010 – Merck Serono, a...
- Exelixis Announces Restructuring
- - Aligning Resources with Late-Stage Compounds XL184,
XL147 and XL765 -
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 8, 2010 -
Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a
consequence of its continued strategy to focus...
- Nabi Closes License Deal With Glaxosmithkline
- From Associated Press (March 8, 2010)
ROCKVILLE, Md. -- Nabi Pharmaceuticals said Monday it closed an
option and license agreement for the smoking vaccine candidate
NicVAx with GlaxoSmithKline.
The deal is potentially worth more than $500 million,...
- Mylan Rebukes and Cites Flaws in Bayer-Sponsored Mylan-Nifedipine Extended Release Bioequivalence Study in Canada
- TORONTO, March 9 /CNW Telbec/ - Mylan (Nasdaq: MYL) today
reported that it has identified multiple flaws within a purported
bioequivalence study sponsored by Bayer Inc. of Canada. The study
compared Bayer's antihypertensive Adalat(R) XL(R) tablets,...
- Roche Suspends Arthritis Drug Study After Deaths
- From Associated Press (March 8,
2010)
BASEL, Switzerland -- Swiss
pharmaceutical company Roche Group
said Monday it has suspended a late-stage trial for a new
rheumatoid arthritis and lupus drug after several patients died
from...
- Roche and Biogen Idec Decide to Suspend Ocrelizumab Treatment - Rheumatoid Arthritis Development Programme on Hold
- Future of the Ocrelizumab RA clinical programme under
evaluation
Basel, Switzerland, March 8, 2010--Roche
and Biogen Idec announced
today their decision to suspend Ocrelizumab
treatment of patients in the Rheumatoid Arthritis
(RA)...
- Isis Earns $6 Million Milestone Payment From Bristol-Myers Squibb for BMS-PCSK9Rx
- CARLSBAD, Calif., March 8, 2010
/PRNewswire via COMTEX/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has
earned a $6 million milestone payment from
Bristol-Myers Squibb Company (NYSE: BMY)
related to the acceptance of...
- XenoPort Restructures to Focus on Key Programs
- SANTA CLARA, Calif.--(BUSINESS WIRE)--Mar 5, 2010 - XenoPort,
Inc. (Nasdaq:XNPT) announced today a restructuring that includes an
overall reduction in its workforce of approximately 50%. The
restructuring is designed to focus the Company's resources...
- La Jolla Pharmaceutical Announces Termination of Merger Agreement with Adamis Pharmaceuticals
- SAN DIEGO--(BUSINESS WIRE)--Mar 5, 2010 - La Jolla
Pharmaceutical Company (Pink Sheets: LJPC) today announced that La
Jolla and Adamis Pharmaceuticals Corporation (OTCBB: ADMP) have
agreed to terminate their merger agreement relating to the...
- Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
- LITTLETON, Colo., March 4 /PRNewswire-FirstCall/ -- Chay
Enterprises, Inc. (OTC:CHYE) (BULLETIN BOARD: CHYE) is pleased to
announce today that the company has merged with DMI Life Sciences,
Inc to form Ampio Pharmaceuticals, Inc. Ampio...
- Pfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9M
- Pfizer CEO Gets 12.5 Percent Raise From Last Year's $14.9M [The
Day, New London, Conn.]
From Day, The (New London, CT) (March 4, 2010)
Mar. 4--As Pfizer Inc. continues a series of layoffs that are
expected to total nearly 20,000 by the time its...
- Pfizer, Bristol-Myers Say Clot Drug Meets Goals
- From Associated Press (March 5, 2010)
NEW YORK -- Bristol-Myers Squibb Co. and Pfizer Inc. on Thursday
said their blood thinner apixaban was more effective than
Sanofi-Aventis’ Lovenox in a late stage clinical trial.
The study compared the...
- Grassley Statement on GAO Report about FDA Office of Criminal Investigations
- M E M O R A N D U M
TO: Reporters and Editors
RE: FDA Criminal Division
DA: Thursday, March 4, 2010
Senator Chuck Grassley issued the comment below about a newly
released report of the Government Accountability Office regarding
the criminal division...
- Abbott Executives To Chair Medical Device Lobby
- From Associated Press (March 4, 2010)
WASHINGTON -- The medical device industry’s chief advocacy
group, AdvaMed, said Thursday an Abbott Laboratories executive will
serve as its chairman.
James Mazzo is President of Abbott Medical Optics, a...
- Unilife and sanofi-aventis Agree to Exclusivity List for Unifill Ready-to-Fill Syringe
-
LEWISBERRY, Pa., March 2 /PRNewswire-FirstCall/ -- Unilife
Corporation ("Unilife" or "Company") (NASDAQ:UNIS) , today announced that it has
agreed to a list of therapeutic drug classes ("Exclusivity List")
within which sanofi-aventis...
- Merck Statement on Vioxx Judgment in Australia
- WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Mar 5, 2010 - Today,
the Federal Court in Australia published its judgment in the
Peterson case. The Court found against MSD Australia on two claims
under Australian statutory provisions. The Court...
- District Court Upholds FDA's Grant of 5-Year Market Exclusivity to VYVANSE(R)
- PHILADELPHIA, March 4, 2010/PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical
company, announces that the United States District Court for the
District of Columbia ("Court"), following extensive...
- H. Lundbeck A/S (DK) - Fourth Quarter and Full Year Report 2009 - Lundbeck Delivers 22 Percent Revenue Growth for 2009 and Meets Financial Expectations for 2009
- COPENHAGEN, March 4, 2010--H. Lundbeck A/S
(Lundbeck) announces 2009 results, which meet financial forecasts
and continue to show growth in all regions. Full year revenue
was DKK 13,747 million and increased 22% at
constant exchange rates compared...
- NICE Appraisal of azacitidine for Myelodysplastic Syndromes
- LONDON, March 4, 2010--The National Institute for Health and
Clinical Excellence (NICE) is currently appraising the use of
azacitidine (Vidaza, Celgene) for myelodysplastic syndromes. In the
final draft guidance, published today (4 March 2010), NICE...
- Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma Strategy in Meeting with Investment Community
- Well-Positioned to Deliver
in 2010 and On Track to Execute BioPharma Strategy
Provides 2013 Minimum
Non-GAAP EPS Guidance
Will Present In-Depth
Review of Robust, Differentiated Pipeline
NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 - During a meeting...
- KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs
-
Judge Sentences St. Louis-Based Company to Pay $27.6 Million
in Fines, Restitution and Forfeitures
WASHINGTON, March 2 /PRNewswire-USNewswire/ -- Ethex
Corporation, a wholly owned subsidiary of St. Louis-based drug
manufacturer, KV...
- Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' Crinone Progesterone Gel Product Line
- - Established, patient-preferred infertility treatment - -
Expands Watson's Women's Health brand product portfolio - - Preterm
birth clinical trials currently underway - - Company acquires 11.2
million shares of Columbia common stock -
MORRISTOWN,...
- Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
- Watson to acquire rights to
CRINONE® and
PROCHIEVE® and 11.2 million shares of
common stock for upfront and milestone payments of up to $92.5
million plus royalties
Also announces contingent agreements to retire
debt
Investor conference call...
- Danish Lundbeck to Launch Two Depression Drugs in Phase III
- From Nordic Business Report (March 3, 2010)
3 March 2010 - Danish pharma company H Lundbeck
A/S (CPH: LUN) and its R&D partner Japanese
TakedaPharmaceutical Company Ltd (TYO:
4502) said today they will start pivotal clinical phase III...
- Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine
- PRINCETON, N.J. & IRVINE, Calif.--(BUSINESS WIRE)--Mar 3,
2010 - Bristol-Myers Squibb Company (NYSE:
BMY) and Allergan
, Inc. (NYSE: AGN) today announced a global
agreement for the development and commercialization of
AGN-209323, a Phase...
- Lundbeck and Takeda Finalize Plans to Initiate Phase III Pivotal Clinical Trials with Lu AA21004 and Lu AA24530
- OSAKA, March 3, 2010--H. Lundbeck A/S (Lundbeck) and Takeda
Pharmaceutical Company Limited (Takeda) today jointly announced the
plans for the additional clinical phase III studies on Lu AA21004
and phase III studies on Lu AA24530 in patients with...
- Teva Announces Favorable Court Ruling in Generic Hyzaar and Cozaar Litigation
- JERUSALEM--(BUSINESS WIRE)--Mar 2, 2010 - Teva Pharmaceutical
Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Court
of Appeals for the District of Columbia Circuit has ruled in Teva's
favor by overturning a July 31, 2009, district court...
- FDA Grants Final Approval For Generic Flomax
- From Associated Press (March 2, 2010)
HAYWARD, Calif. -- Drugmaker Impax Laboratories Inc. said
Tuesday the Food and Drug Administration gave final approval to its
generic version of the enlarged prostate treatment Flomax.
Impax plans to start...
- Dendreon Rises; FDA Says No Meeting on Provenge
- From Associated Press (March 2, 2010)
WASHINGTON -- Shares of biotechnology company Dendreon Corp.
jumped Tuesday after federal regulators said they don’t plan
to hold a public meeting on the company’s prostate cancer
treatment, possibly...
- Nabi Shareholders Approve Deal With Glaxo
- From Associated Press (March 2, 2010)
ROCKVILLE, Md. -- Nabi Biopharmaceuticals said Tuesday
shareholders approved its option and license agreement for the
smoking vaccine candidate NicVAx with GlaxoSmithKline.
More than 73 percent of Nabi’s...
- Bristol-Myers Squibb Names Lamberto Andreotti CEO, Effective May 4; James Cornelius to Retire as CEO, Remain as Chairman
- NEW YORK--(BUSINESS WIRE)--Mar 2, 2010 -
Bristol-Myers Squibb Company (NYSE:BMY) today announced that
Lamberto Andreotti, 59, has been designated by the Board of
Directors to serve as the company's chief executive officer,
effective May 4, when...
- Abbott and Enanta Announce Advancement of Hepatitis C Collaboration
- Initiation of Phase 2 Clinical Trial Investigating Three
Individual HCV Antivirals
ABBOTT PARK, Ill. and WATERTOWN, Mass., March 2
/PRNewswire-FirstCall/ -- Abbott (NYSE:ABT) and Enanta Pharmaceuticals announced
today the advancement of their...
- Med Ad News' 21st Annual Manny Awards Will Honor Healthcare Advertising Agencies
- MED AD NEWS' 21ST ANNUAL MANNY AWARDS WILL HONOR HEALTHCARE
ADVERTISING AGENCIES
NEWTOWN, Pa., March 2, 2010 - - On Thursday, April 22,
2010, Med Ad News magazine will host its 21st Annual Manny Awards
celebrating creative excellence in...
|
